Healthcare

  • |

    Billionaire Fan Club, Gold Penthouse Edition

    ByJustin Jest

    If you’re not a billionaire and you still keep showing up for the guy in the gold tower—congrats. You watched unions get busted, factories get shipped overseas, healthcare get pricier, and wages stay flat… and you still chose the billionaire fan club like it’s your team.

    Meanwhile the “care” campaign is doing its best private-club magic: gold penthouse, VIP elevators, zero taxes, max profits, “make you believe again,” “finally someone who cares!” The only thing getting protected is the vibe—because the elevator’s going to the penthouse, and the rest of you are paying for the ride with your real life.

  • |

    Freeze the fraud—don’t freeze the care: Stop Enrolling the Truth

    ByHarlan Quill

    “Freeze the fraud, not the care” sounds like a targeted plan until you notice the workflow only knows one setting: OFF. If the villains are “bad actors,” why does the “stop enrollment freeze” also slap new providers with “home health application—denied” and “hospice application—denied,” while pretending the lock is aimed at somebody else?

    The honest incentive is simple: it’s easier to freeze paperwork than to triage individuals. Current providers can keep limping along, sure, while new enrollment gets frozen like we’re all waiting for the government to invent case-by-case judgment. And that’s how “prosecute fraud” turns into “don’t punish seniors who need care at home,” except the punishing part is baked into the calendar—where’s the functioning adult with the plan?

  • |

    Promises, Promises: The Healthcare Gradebook

    ByBrick Tungsten

    Folks, gather ’round the grill because it’s time for one of my classic freedom sermons. Remember those grand healthcare promises? They promised us a backyard BBQ of savings and sizzle, but handed us a platter of stale chips. Our premiums have gone up faster than a hot dog at a baseball game, and access to care is doing the limbo—how low can it go? It’s like promising Betsy a new set of tires and giving her a tricycle.

    Now, don’t get me wrong—I’m all for a little porch talk on liberty and savings. But it’s high time we admit that lower costs have somehow translated into higher prices and fewer options. You can’t call it cheaper healthcare if no one can afford or access it, like calling tofu the steak of the future. Let’s saddle up and sort out these promises before they disappear in a cloud of grill smoke and good intentions.

  • |

    Pro-Worker Policy vs. The Great Distraction: A Parable

    ByMoses Pray

    In these peculiar times, while some prefer turning every corner into a battleground for the latest culture skirmish, many laborers simply yearn for good old-fashioned support. Imagine if, instead of battling over bookstore shelving or cafeteria pronouns, we focused on providing average folks something tangible to hold onto, like jobs and fair wages. You’d think that kind of common sense would catch on, wouldn’t you? Yet, here we are, tiptoeing through the minefield of slogans as if the road to prosperity were paved with rhetoric alone.

    Picture a life where a Child Tax Credit isn’t just a line on a bill but a real blessing. Where Medicare isn’t a political football but an actual help to Nana and Gramps. Now, imagine legislation that deeply respects the laborer without needing a political sermon. Workers recognize blessings by action, not just words. Perhaps it’s time we remember that solid bridges and secure jobs are the truest symbols of support—not just yard signs. Amen to real progress.

  • |

    When a Virtual Check‑In Feels Like a Paperwork Excuse: OIG Unearths $2.26 Million in Sketchy Remote Visits

    ByHugh Jass

    In an April 23, 2026 audit from the Office of Inspector General (OIG), a long-hidden bureaucratic gem emerged—approximately $2.26 million in potentially improper Medicare payments for virtual check-ins and e-visits. Reading like the diary nobody locked, this audit finds that something was amiss in the virtual halls of healthcare billing.

    This isn’t just about imaginary band-aids on imagined cuts. It’s about weaknesses in oversight that allowed these virtual care payments to balloon into multimillion-dollar windfalls, all while CMS was haunted by gaps in system edits and provider education. The very nature of paperwork itself stands accused of duplicity.

    The OIG report breaks it down: around $1.96 million tied to virtual check-ins coincided suspiciously with recent or next-day Evaluation/Management visits. Meanwhile, duplicate billing during e-visits added another $298,200 to the tab. In total, 173,287 services went unnoticed under timelines tighter than a bureaucrat’s grip on their favorite pen.

    No, it’s not fraud; we’re talking ‘potentially improper’—a distinction as sharp and necessary as the label on a mystery envelope that says, ‘Do Not Open.’ The blame lies partly with missing system edits in CMS and the MACs, compounded by bewildered providers deciphering modifiers like an undecided jury.

    The Office of Inspector General, with the calm gravitas of a librarian discovering a hidden annex, offered a roadmap: implement system edits (which CMS accepted), fortify code descriptions (less enthusiasm there), and bolster provider education (agreed upon with the eagerness of a clerk discovering extra forms to file).

    So why should this matter? Because it’s taxpayer money squirming away through administrative fissures. The report’s findings underscore just how bizarrely captivating paperwork can be—we don’t always see the full story unless someone turns on the filing cabinet’s lamp.

    Remember: this isn’t just a tale of fiscal oversight missing a beat. It’s about the modifiers that walked in wearing suspiciously innocent labels, revealing a system that promises future improvements. Yet, even as edits loom, expect the receipts to keep sweating.

    Sources

  • |

    PhRMA’s Seven-Figure 340B Ad Blitz vs. TrumpRx Lobbying Surge

    ByPhil McCracken

    PhRMA isn’t playing coy. Earlier this month, they rolled out a seven-figure ad campaign targeting the 340B drug discount program, branding it as a cozy corner for hospital exploitation. On the surface: a public service announcement in slick-suit attire. Behind the curtain, though, the same outfit was pouring $12.2 million in Q1 2026 into lobbying efforts—ranking as one of the trade group’s heftiest checks ever written in a quarter, according to Bloomberg Law.

    The paradox here would amuse a cat. While television screens flash with moral indignation over discounted meds for clinics serving the underprivileged, PhRMA’s lobbyists are busy weaving legislative webs in Capitol Hill hallways. If talk is cheap, lobbying clearly doesn’t get the same discount—more like champagne on a shoe-string cut price.

    Here’s the kicker: PhRMA isn’t isolated on this spending spree. As reported by the Sacramento Bee, pharmaceutical companies tied to the TrumpRx initiative shelled out over $130 million in 2025, marking a 23% increase in their lobbying efforts. The narrative is clear: while projecting a wholesome PSA vibe against drug discounts, Big Pharma is wrapping Capitol Hill in a cashmere blanket of influence.

    The 340B program, designed to enable hospitals and clinics to provide affordable meds to needy patients, has been a thorn in PhRMA’s side for a while. They argue the rebates are a windfall for hospitals rather than a direct benefit for patients. You could say it’s a bit like suggesting the hospital uses the program’s ‘gains’ to sneak an espresso machine into the break room.

    Then there’s TrumpRx, a program ostensibly crafted to curb soaring drug prices. Its partners’ heightened lobby spend tells a different story: ensuring the policymaking process is as friendly as a longtime poker buddy.

    The juxtaposition is almost laughable: the louder the commercials, the fatter the lobbying invoices. Public outrage serves as the shiny distraction while the private billing department hums its quiet tune, and yet, who’s footing the bill? Not the executive who’s likely enjoying a cafe’s worth of gratis macchiatos—but rather taxpayers, indirectly contributing to this financial ballet.

    Keep your eyes peeled; as these ad campaigns echo on, the Q2 lobbying disclosures are bound to deliver another round of intrigue—and perhaps, a few more giggles from those tracking lobbyist cologne and receipt trails.

    Sources

  • |

    Court Holds Medicine (and Our Sanity) Hostage—Supreme Court Hits Pause on Abortion-Pill Snafu

    ByMike Rotch

    Folks, buckle up because the Supreme Court has once again chosen to play its favorite game: judicial hot potato. Justice Samuel Alito has hit the snooze button on sense and reason by extending his emergency stay against the Fifth Circuit’s ruling on mifepristone. If you’re keeping score at home, that means telehealth and mail-order access to the abortion pill stay intact until at least this Thursday, May 14, at 5 p.m. ET. It’s just another Tuesday in our democracy, where clarity is a pipe dream.

    Why should you care? Well, if you’re a woman who relies on telehealth for reproductive healthcare, this bureaucratic charade means you’re left holding your breath. The Fifth Circuit’s decision that was supposed to go into effect required in-person dispensing of mifepristone, a much more cumbersome process. This decision affects a majority of medication abortions, so the stakes are sky-high for providers and patients trying to plan for, you know, their lives.

    According to AP News, this hold keeps the current pharmacy and mail-access arrangements in place, which is crucial given that in-person requirements would massively curb access to care, especially in states where clinic availability is sparse. Why make something easy when you can wrap it in red tape and douse it in paperwork perfume?

    The joke, if you dare call it that, is on us. While Justice Alito contemplates from the shadow docket, everyone else is left in the kind of limbo that bureaucrats and goblins might call home. Providers have to play a guessing game about what’s legal and what’s not, with patients caught in the middle like political pawns. Thanks, SCOTUS, my blood pressure just filed its own extension.

    The Guttmacher Institute highlighted the true madness here: this isn’t just about an abortion pill; it’s about whether medical care can be managed like a game of Calvinball. With around-the-clock uncertainty, patients and providers deserve better than being dangled by the whims of temporary rulings. But that would require the courage to issue a clear ruling. And courage, apparently, is out of stock.

    Keep your eyes peeled, folks. By Thursday, the Court might decide to extend the stay again—or even rattle everyone with a decision. Until then, the stay is extended, sanity is on lease, and the only consistent thing here is chaos.

    Sources

End of content

End of content